Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05248659 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)

StatusEnrolling by Invitation
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 1 to 158 Completion date: Dec 28, 2028 to Dec 31, 2029 · Eligibility criteria expanded, about 380 words · Study title shortened, about 2 wordsv7 Show 3 more changesShow less
    • Completion date: Dec 28, 2028 to Dec 31, 2029
    • Eligibility criteria expanded, about 380 words
    • Study title shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  2. Re-verified, no change to tracked fieldsv6
  3. Study description shortened, about 14 wordsv5 See this version in full on ClinicalTrials.gov ↗
  4. Re-verified, no change to tracked fieldsv4
  5. Trial status: Active, Not Recruiting to Enrolling by Invitationv3
  6. Trial status: Not Yet Recruiting to Active, Not Recruiting Start date changed from estimate of Mar 2022 to Apr 5, 2022v2 Show 1 more changeShow less
    • Start date changed from estimate of Mar 2022 to Apr 5, 2022
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the long-term safety and tolerability of sibeprenlimab in subjects with IgAN
Trial Details
NCT Number NCT05248659
Lead Sponsor Otsuka Pharmaceutical Development & Commercialization, Inc.
Conditions Immunoglobulin A Nephropathy
Enrollment 600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov